Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Paragon Care Limited is Australia's largest integrated medical equipment and consumables distributor, servicing hospitals, aged care facilities, and primary healthcare providers across Australia and New Zealand. The company operates through a network of specialized distribution businesses covering medical devices, surgical instruments, diagnostic equipment, and healthcare consumables, with recent aggressive M&A expansion driving revenue growth but pressuring margins and cash flow.
Paragon operates as a low-margin, high-volume distributor capturing spread between manufacturer pricing and end-customer sales. The 9% gross margin reflects intense competition in medical distribution, with profitability dependent on operational efficiency, purchasing scale, and cross-selling across product categories. Revenue growth has been M&A-driven (21.7% YoY) through bolt-on acquisitions consolidating fragmented Australian medical supply market. Operating leverage comes from integrating acquisitions onto shared infrastructure, negotiating volume rebates from manufacturers, and expanding service attach rates on equipment sales. Limited pricing power due to hospital procurement processes and government healthcare budget constraints.
M&A announcements and integration execution - company has pursued aggressive roll-up strategy, with market reacting to acquisition multiples and synergy realization
Australian healthcare capital expenditure trends - hospital equipment replacement cycles and government healthcare infrastructure spending directly impact capital equipment sales
Operating cash flow conversion - negative FCF despite positive earnings raises concerns about working capital management and acquisition integration costs
Margin trajectory - ability to expand 2.5% operating margin through procurement synergies and overhead rationalization critical to equity story
Healthcare procurement consolidation - hospital group purchasing organizations (GPOs) and government bulk-buying initiatives compress distributor margins through increased bargaining power and potential disintermediation
Direct-to-customer models from manufacturers - large medical device OEMs (Medtronic, Stryker, etc.) increasingly selling directly to major hospital networks, bypassing distributors and threatening market share in high-margin capital equipment
Regulatory pricing pressure - Australian government pharmaceutical and medical device pricing reforms (Prostheses List reforms) creating deflationary environment for certain product categories
Market share pressure from global distributors - international players like McKesson, Cardinal Health potentially entering Australian market with superior scale and technology platforms
Integration execution risk - aggressive M&A strategy (evident in 21.7% revenue growth) creates operational complexity, with failure to realize synergies threatening margin recovery and cash generation
Negative free cash flow of -$0.0B despite positive net income signals working capital strain or elevated capex/acquisition costs, raising liquidity concerns if operating performance deteriorates
Debt/equity of 0.93x creates refinancing risk in rising rate environment, particularly given compressed margins (0.6% net margin) leave limited buffer for interest coverage deterioration
Goodwill and intangible impairment risk - acquisition-driven growth model typically creates significant goodwill balances vulnerable to write-downs if acquired businesses underperform
low-to-moderate - Healthcare spending is relatively non-discretionary, providing defensive characteristics during downturns. However, elective procedure volumes (which drive consumables demand) correlate with consumer confidence and employment levels. Capital equipment purchases by hospitals are more cyclical, subject to budget constraints and can be deferred during economic stress. Australian government healthcare funding (60%+ of healthcare expenditure) provides stability but creates exposure to fiscal policy changes.
Rising rates negatively impact Paragon through multiple channels: (1) Higher financing costs on 0.93x debt/equity leverage used to fund acquisitions, directly pressuring net margins; (2) Increased discount rates compress valuation multiples for low-margin, capital-intensive distributors; (3) Hospital customers may delay capital equipment purchases when financing costs rise; (4) M&A multiples typically compress in higher rate environments, reducing strategic optionality. The 6.9x EV/EBITDA valuation suggests market already pricing in rate sensitivity.
Moderate credit exposure through two channels: (1) Customer credit risk from hospital networks and aged care facilities, though government-backed institutions represent lower default risk; (2) Supplier financing arrangements and inventory funding requirements create working capital sensitivity to credit availability. Negative operating cash flow indicates potential liquidity pressure if credit conditions tighten, particularly given ongoing acquisition integration needs.
value - The 0.1x P/S, 1.1x P/B, and 6.9x EV/EBITDA multiples indicate deep value territory, attracting contrarian investors betting on margin recovery and cash flow normalization post-integration. The -61.5% one-year return suggests significant negative sentiment, creating potential turnaround opportunity for value-oriented funds. However, negative FCF and execution risks deter growth investors despite 21.7% revenue growth.
high - The -30% three-month and -47.5% six-month returns demonstrate elevated volatility typical of small-cap ($0.3B market cap) companies with execution risk. Healthcare distribution typically exhibits moderate volatility, but Paragon's aggressive M&A strategy, margin pressure, and cash flow concerns amplify stock price sensitivity to quarterly results and integration updates. Limited liquidity in small-cap Australian equities exacerbates price swings.